VNRX
What one share of VolitionRx Limited holds
In Vitro and In Vivo Diagnostic Substances
Imagine a world where diseases like cancer and sepsis can be diagnosed early and monitored easily using routine blood tests. That’s the world Volition is trying to build by developing its innovative family of simple, easy to use, cost-effective blood tests.
VolitionRx Limited’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.36 |
|---|---|
| Profit | −$3.74 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$2.85 |
| Cash and investments | $0.23 |
| Debt | $0.61 |
| Book value | −$2.67 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$10.33 | $0.36 | −$8.05 | — | $16.21 |
| 2017 | — | −$11.19 | $1.08 | −$10.32 | — | $7.51 |
| 2018 | — | −$11.47 | −$0.19 | −$9.20 | — | $6.87 |
| 2019 | $0.01 | −$8.22 | $0.26 | −$6.76 | — | $6.91 |
| 2020 | $0.01 | −$9.01 | $0.86 | −$8.13 | — | $6.70 |
| 2021 | $0.03 | −$10.25 | $0.37 | −$8.29 | — | $6.59 |
| 2023 | $0.22 | −$10.02 | $0.30 | −$5.38 | — | −$1.91 |
| 2024 | $0.29 | −$6.23 | $0.06 | −$6.05 | — | −$5.18 |
| 2025 | $0.32 | −$4.37 | $0.02 | −$3.70 | — | −$5.45 |